e-learning
resources
Virtual 2020
Pre-Congress Content
Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
A. Zinchenko (St. Petersburg, Russian Federation), L. Novikova (St. Petersburg, Russian Federation), M. Ilkovich (St. Petersburg, Russian Federation)
Source:
Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Session:
Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Session type:
E-poster session
Number:
3405
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Zinchenko (St. Petersburg, Russian Federation), L. Novikova (St. Petersburg, Russian Federation), M. Ilkovich (St. Petersburg, Russian Federation). Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up. 3405
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Related content which might interest you:
Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019
Chemotherapy in patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018
Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis
Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017
Year: 2018
Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Multisystemic Langerhans cell histiocytosis unresponsive to aggressive chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 383s
Year: 2006
Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Clinical course and outcome of pulmonary Langerhans‘-cell histiocytosis
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Cladribine improves lung cysts and pulmonary function in a child with histiocytosis
Source: Eur Respir J 2015; 45: 831-833
Year: 2015
Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation
Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases
Year: 2017
Langerhans' cell histiocytosis: clinical and diagnostic features and response to therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 219s
Year: 2001
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients
Source: Eur Respir Rev 2013; 22: 93-95
Year: 2013
Pneumothorax in patients with Langerhans cell histiocytosis
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
Long-term follow-up of patients with pulmonary sarcoidosis
Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Year: 2018
Cladribine as a second line treatment in a child with isolated pulmonary Langerhans cell histiocytosis – case report
Source: International Congress 2018 – Orphan diseases in children
Year: 2018
Treatment of pulmonary Langerhans cell histiocytosis with multifocal involvement with vinblastine, prednisolon, mercaptopurine
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
How I manage pulmonary Langerhans cell histiocytosis
Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017
Year: 2017
Smoking status and long term clinical outcome in patients with pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Paediatric pulmonary Langerhans cell histiocytosis
Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020
Year: 2020
Lung transplantation for pulmonary Langerhans‘ cell histiocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 635s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept